Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
A reference sequence for this emerging model organism will facilitate research on type 2 diabetes and the health effects of circadian rhythm disruption.
Researchers integrate scRNA-seq, spatial transcriptomics, and histology imaging data to show that spatial cellular architecture predicts glioblastoma prognosis.
The once white-hot investment climate for proteomics has cooled, sending companies scrambling to recast themselves. Biotech analysts and investors say interest in proteomics companies peaked about a year ago with a rash of them competing in the technology and database sectors. In Europe, proteomics companies have also experienced a downturn, with biotech stocks falling 40% from their peak in 2000. Developing a new generation of technology and digitally mapping the proteome was, relatively speaki
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
The Scientist Marketing Team | Feb 20, 2013 | 6 min read
The Scientist takes a bold look at what the future holds for DNA research, bringing together senior investigators and key leaders in the field of genetics and genomics in this 3-part webinar series.
The Scientist and Jerome Siegel | Mar 1, 2016 | 10+ min read
Once believed to be unique to birds and mammals, sleep is found across the metazoan kingdom. Some animals, it seems, can’t live without it, though no one knows exactly why.
Alicia Ault(aault@the-scientist.com) | Jul 17, 2005 | 6 min read
James C. Foster, CEO of Charles River Laboratories, celebrated the company's five years of public trading by ringing the closing bell at the New York Stock Exchange on June 13.